Literature DB >> 24359985

Myeloma-related kidney disease.

Nelson Leung1, Samih H Nasr2.   

Abstract

Multiple myeloma is a malignant plasma cell disorder characterized by the overproduction of monoclonal proteins. The kidney is 1 of the major target organs of multiple myeloma. Most often, this is the result of the monoclonal proteins, which can injure the kidney via several mechanisms. In some cases, direct invasion by myeloma cells and/or bone marrow cells can also result in kidney injury. A kidney biopsy can help distinguish the various myeloma-related kidney diseases and aid in the treatment plan.
Copyright © 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amyloidosis; Cast nephropathy; Kidney; MIDD; Multiple myeloma

Mesh:

Substances:

Year:  2014        PMID: 24359985     DOI: 10.1053/j.ackd.2013.08.009

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  12 in total

1.  Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.

Authors:  Heinz Ludwig; Elisabeth Rauch; Thomas Kuehr; Zdeněk Adam; Adalbert Weißmann; Hedwig Kasparu; Eva-Maria Autzinger; Daniel Heintel; Richard Greil; Wolfram Poenisch; Ercan Müldür; Niklas Zojer
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

2.  Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients.

Authors:  M Vignon; V Javaugue; M P Alexander; K El-Karoui; A Karras; D Roos-Weil; B Royer; B Asli; B Knebelmann; G Touchard; A Jaccard; B Arnulf; F Bridoux; N Leung; J P Fermand
Journal:  Leukemia       Date:  2016-07-20       Impact factor: 11.528

3.  Acute Kidney Injury in Patients Receiving Systemic Treatment for Cancer: A Population-Based Cohort Study.

Authors:  Abhijat Kitchlu; Eric McArthur; Eitan Amir; Christopher M Booth; Rinku Sutradhar; Habeeb Majeed; Danielle M Nash; Samuel A Silver; Amit X Garg; Christopher T Chan; S Joseph Kim; Ron Wald
Journal:  J Natl Cancer Inst       Date:  2019-07-01       Impact factor: 13.506

4.  Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era.

Authors:  Michael B Stokes; Anthony M Valeri; Leal Herlitz; Abdullah M Khan; David S Siegel; Glen S Markowitz; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2015-09-15       Impact factor: 10.121

5.  Remission of light chain proximal tubulopathy in IgG λ-type multiple myeloma by lenalidomide and dexamethasone therapy.

Authors:  Shinya Kawamoto; Yuji Hidaka; Yu Kaneko; Hideo Misawa; Katsuhiro Nagahori; Atsunori Yoshino; Takamitsu Okamura; Shinichi Ban; Yoshihiko Ueda; Tetsuro Takeda
Journal:  CEN Case Rep       Date:  2019-02-05

6.  An Atypical Kidney-Related Presentation of Multiple Myeloma.

Authors:  Monique Pereira Rêgo Muniz; João Batista da Silva Neto; Gyl Eanes Silva
Journal:  Kidney360       Date:  2021-07-29

7.  Cast nephropathy: an extremely rare renal presentation of Waldenström's macroglobulinaemia.

Authors:  Tânia Santos; Susana Machado; Vítor Sousa; Mário Campos
Journal:  BMJ Case Rep       Date:  2015-10-07

Review 8.  Acute kidney injury in critically ill cancer patients: an update.

Authors:  Norbert Lameire; Raymond Vanholder; Wim Van Biesen; Dominique Benoit
Journal:  Crit Care       Date:  2016-08-02       Impact factor: 9.097

9.  Comparison of two melphalan protocols and evaluation of outcome and prognostic factors in multiple myeloma in dogs.

Authors:  Ricardo Fernández; Esther Chon
Journal:  J Vet Intern Med       Date:  2018-03-22       Impact factor: 3.333

10.  Clinical Presentation, Renal Histopathological Findings, and Outcome in Patients with Monoclonal Gammopathy and Kidney Disease.

Authors:  Gaetano Alfano; Alice Delrio; Francesco Fontana; Giacomo Mori; Silvia Cazzato; Annachiara Ferrari; Rossella Perrone; Silvia Giovanella; Giulia Ligabue; Riccardo Magistroni; Gianni Cappelli
Journal:  Int J Nephrol       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.